El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

896536.pdf (1.06 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-07-11

Llicència de publicació

cc-by (c) Irene Lizano-Díez et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222509

Assessment of mandatory declaration excipients in pediatric off label prescriptions in Spain.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/https://doi.org/10.1038/s41598-025-11647-x

Resum

Pediatric patients are at increased risk of exposure to potentially harmful excipients when receiving off-label medicinal products primarily formulated for adults, raising concerns about adverse events. Based on data from a previously published study, this research focuses on the most frequently prescribed off-label medicinal products in order to assess the safety of their excipients. The aim was to identify Excipients of Mandatory Declaration (EMDs) that could pose additional safety risks in individuals under the age of 18. A descriptive, and retrospective observational population-based study in individuals under 18 was developed in the Spanish primary care setting between the years 2004–2005 and 2017–2020. The main data source was proprietary database, with nationwide coverage of prescriptions. The analysis included 4,922,984 off-label prescriptions, accounting for 16 active ingredients and 37 medicinal products (18 oral, 16 topical and three inhaled) that were scrutinized for EMD composition. Neonates and infants up to five years old accounted for nearly 50% of all off-label prescriptions among the under-18 population, exposing them to additional safety risks from potentially harmful EMDs in these formulations, which may lead to severe adverse events, causing permanent or long-term harm. The degree of harm of EMDs was assessed overall as “severe” for nine out of 22 EMDs, mostly used for oral formulations, and “moderate” for six EMDs. No EMDs were categorized as “no harm”. Results on EMDs in oral medicinal products, for instance, highlight the urgent unmet needs in this regard, especially for young children; EMDs like sodium, sorbitol, propylene glycol and sweeteners often exceeded EMA-recommended thresholds. This study underscores the need to address risks linked to off-label use of medicinal products in children, particularly those related to EMDs. Integrating excipient risk warnings into prescribing systems and monitoring related adverse events is strongly recommended.

Matèries

Medicaments, Prescripció de medicaments, Pediatria

Matèries (anglès)

Drugs, Drug prescribing, Pediatrics

Citació

Col·leccions

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Citació

LIZANO DÍEZ, Irene, ALDALUR-URANGA, Itziar, BRAZA REYES, Antonio j., FIGUEIREDO ESCRIBÁ, Carlos de, VIÑAS BASTART, Montserrat, MARIÑO HERNÁNDEZ, Eduardo l., MODAMIO CHARLES, Pilar. Assessment of mandatory declaration excipients in pediatric off label prescriptions in Spain.. _Scientific Reports_. 2025. Vol. 26293. [consulta: 5 de gener de 2026]. ISSN: 2045-2322. [Disponible a: https://hdl.handle.net/2445/222509]

Exportar metadades

JSON - METS

Compartir registre